Asthma is a heterogeneous lung disease with variable phenotypes (clinical presentations)
and distinctive endotypes (mechanisms). Over the last decade, considerable efforts have …

Executive summary Asthma is responsible for considerable global morbidity and health-care
costs. Substantial progress was made against key outcomes such as hospital admissions …

Patients with severe uncontrolled asthma have disproportionally high morbidity and
healthcare utilization as compared with their peers with well-controlled disease. Although …

Background Benralizumab is a humanised, afucosylated, anti-interleukin-5 receptor α
monoclonal antibody that induces direct, rapid, and nearly complete depletion of …

Five biologicals have been approved for severe eosinophilic asthma, a well‐recognized
phenotype. Systematic reviews (SR) evaluated the efficacy and safety of benralizumab …

Summary Background Black and Hispanic children living in urban environments in the USA
have an excess burden of morbidity and mortality from asthma. Therapies directed at the …

Guideline-based management of asthma focuses on disease severity and choosing the
appropriate medical therapy to control symptoms and reduce the risk of exacerbations …

Systemic type 2 inflammation encompassing T helper 2 (TH2)-type responses is emerging
as a unifying feature of both classically defined allergic diseases, such as asthma, and a …

Asthma varies considerably across the life course. Childhood asthma is known for its overall
high prevalence with a male predominance prior to puberty, common remission, and rare …

Severe or therapy-resistant asthma is increasingly recognised as a major unmet need. A
Task Force, supported by the European Respiratory Society and American Thoracic Society …